
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing notable year-over-year growth in its Flexible Solutions Provisioning (FSP), Real World Evidence (RWE), and Clinical Solutions Management Services (CSMS) segments, indicating strong operational performance in Q3. The company is also benefiting from improved decision timelines and a robust pipeline within its commercial segment, largely fueled by recent drug launches. Additionally, IQVIA is projecting a growth rate of over 4% in its Research and Development Solutions segment on a constant currency basis, reflecting a favorable pricing environment and strategic management of contract negotiations.
Bears say
IQVIA Holdings experienced a decline in year-over-year constant currency (CC) growth, which fell to 3.8%, compared to 6.8% in the previous quarter, indicating challenges in maintaining robust revenue growth rates. The company has expressed that it would be dissatisfied with reported revenue growth below 5% for 2026, reflecting a cautious outlook amidst pressures such as margin headwinds from passthroughs and the impact of rising interest rates on earnings. Furthermore, individual segments showed organic CC growth that was uneven, with the Technology and Analytics Solutions (TAS) segment facing the most significant challenges, leading to concerns about the overall ability to sustain positive growth momentum.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares